CRP and lung carcinoma: Clinically, six-week selective inhibition of COX-2, using celecoxib, reduced the severity of cachexia symptoms in lung cancer patients through improving muscle strength and lowering the circulating levels of C-reactive protein (CRP) (marker of systemic inflammation) [60].